<DOC>
	<DOCNO>NCT01644994</DOCNO>
	<brief_summary>The aim introduce new therapeutic method intracavitary chemotherapy ( cisplatin ) combine fibrin carrier ( Vivostat® ) pleurectomy/decortication extrapleural pneumonectomy phase I II study Malignant Pleural Mesothelioma patient evaluation safety dose-escalating model ( phase I ) , confirmation safety efficacy phase II maximum tolerate dose phase I .</brief_summary>
	<brief_title>Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D EPP Malignant Pleural Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : Patient able understand willing sign write informed consent document . Male female , age &gt; =18 year ECOG performance status = &lt; 2 Resectable MPM histologically confirm ( phase I : stage cT1cT4 cN0cN3 cM0cM1 / phase II : stage cT1cT3 cN0cN1 cM0 ) Only Phase II : Mediastinal staging ( cytological histological ) Only Phase II : Induction chemotherapy ( 3 cycle cisplatin carboplatin combine pemetrexed ) Patient qualify pleurectomy/decortication ( P/D ) extrapleural pneumonectomy ( EPP ) resection MPM , assess multidisciplinary tumor board include thoracic surgeon Patient must appropriate organ bone marrow function define : hematologic function : hemoglobin ≥100 g/L , WBC ≥3.5 x G/L , neutrophils ≥1.5 x G/L , thrombocytes ≥100 x G/L ; liver function : total bilirubin LDH ≤1.5 ULN ; AST , ALT , GGT , AP ≤2.5 ULN ; renal function : creatinine ≤130 μmol/L , great , creatinine clearance ≥60 ml/min/1.73m2 . Patient must appropriate blood coagulation P/D EPP ( Quicktest &gt; 50 % , aPTT within normal institutional limit , INR &lt; =1.2 ) The patient agree use efficient contraceptive treatment 3 month cisplatin application require ( premenopausal woman men sexually mature age ) . Heart lung function allow P/D general anesthesia Exclusion criterion : Known suspected unwillingness patient follow rule protocol Patient recover side effect prior chemotherapy radiotherapy . Any known hypersensitivity cisplatin platinum contain substance component use preparation drug . Patient must receive investigational agent 4 week treatment end observation period ( 2 month treatment ) . Patient prior ipsilateral pleurectomy Only Phase II : Multimodality Prognostic Score ( MMPS ) &gt; 2 : 4 item maximum possible score 4 patient present four condition 0 none present : Tumor volume induction chemotherapy &gt; 500 ml , nonepithelioid histotype diagnostic biopsy induction chemotherapy , CRP value &gt; 30 mg/l induction chemotherapy , progressive disease induction chemotherapy accord RECIST criterion Patient uncontrolled intercurrent illness would limit operative procedure P/D / EPP compliance study requirement Tinnitus impairment severity grade I ( slight ) evaluate tinnitus questionnaire MiniTF12_CH , and/or restrict power hear 4 kHz confirm audiometry , unless agerelated presbyacusis normal range confirm audiologist . Known alcohol and/or drug abuse time screen Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>